Specgx Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SPECGX LLC, and when can generic versions of SPECGX LLC drugs launch?
SPECGX LLC has sixty approved drugs.
There is one US patent protecting SPECGX LLC drugs.
There are ten patent family members on SPECGX LLC drugs in nine countries and thirty supplementary protection certificates in ten countries.
Summary for Specgx Llc
| International Patents: | 10 |
| US Patents: | 1 |
| Tradenames: | 47 |
| Ingredients: | 31 |
| NDAs: | 60 |
| Drug Master File Entries: | 73 |
Drugs and US Patents for Specgx Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specgx Llc | HYDROMORPHONE HYDROCHLORIDE | hydromorphone hydrochloride | TABLET;ORAL | 076855-001 | Dec 23, 2004 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Specgx Llc | MORPHINE SULFATE | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 076412-002 | Jul 31, 2003 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Specgx Llc | LISDEXAMFETAMINE DIMESYLATE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 211840-006 | Aug 25, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Specgx Llc | IMIPRAMINE HYDROCHLORIDE | imipramine hydrochloride | TABLET;ORAL | 087846-002 | May 22, 1984 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Specgx Llc | LISDEXAMFETAMINE DIMESYLATE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 211840-003 | Aug 25, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Specgx Llc | VIGABATRIN | vigabatrin | FOR SOLUTION;ORAL | 212626-001 | Jul 28, 2021 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Specgx Llc | EXALGO | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021217-001 | Mar 1, 2010 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Specgx Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Specgx Llc | RESTORIL | temazepam | CAPSULE;ORAL | 018163-003 | Oct 25, 1991 | 5,326,758 | ⤷ Try a Trial |
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013-004 | Approved Prior to Jan 1, 1982 | 3,922,305 | ⤷ Try a Trial |
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013-001 | Approved Prior to Jan 1, 1982 | 3,922,305 | ⤷ Try a Trial |
| Specgx Llc | EXALGO | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021217-004 | Aug 24, 2012 | 5,914,131 | ⤷ Try a Trial |
| Specgx Llc | RESTORIL | temazepam | CAPSULE;ORAL | 018163-003 | Oct 25, 1991 | 5,211,954 | ⤷ Try a Trial |
| Specgx Llc | EXALGO | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021217-003 | Mar 1, 2010 | 5,914,131 | ⤷ Try a Trial |
| Specgx Llc | RESTORIL | temazepam | CAPSULE;ORAL | 018163-003 | Oct 25, 1991 | 5,030,632 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SPECGX LLC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 5 mg/5 mL and 10 mg/5 mL | ➤ Subscribe | 2010-04-13 |
International Patents for Specgx Llc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2005035000 | ⤷ Try a Trial |
| Austria | 526988 | ⤷ Try a Trial |
| Canada | 2540052 | ⤷ Try a Trial |
| Japan | 4959335 | ⤷ Try a Trial |
| China | 1867359 | ⤷ Try a Trial |
| Mexico | PA06003725 | ⤷ Try a Trial |
| European Patent Office | 1680144 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Specgx Llc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2316456 | SPC/GB17/078 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE.; REGISTERED: UK EU/1/14/988 20150330; UK PLGB 50742/0001 20150330 |
| 2316456 | 132017000142109 | Italy | ⤷ Try a Trial | PRODUCT NAME: NALTREXONE/BUPROPIONE(MYSIMBA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/988, 20150330 |
| 1644019 | 122013000079 | Germany | ⤷ Try a Trial | PRODUCT NAME: LISDEXAMFETAMINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DESSEN, WIE L-LYSIN-D-AMPHETAMIN-MESYLAT; REGISTRATION NO/DATE: 86155.00.00 86156.00.00 86157.00.00 20130318; FIRST REGISTRATION: UK PL 08081/0050-2 20130201 |
| 0566709 | SPC/GB04/012 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925 |
| 1644019 | SPC/GB13/052 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: LISDEXAMFETAMINE OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; REGISTERED: UK PL08081/0050-2 20130201; UK PL08081/0062-4 20130201 |
| 0836511 | CA 2006 00019 | Denmark | ⤷ Try a Trial | PRODUCT NAME: FENTANYL HYDROCHLORID |
| 0901368 | C300523 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
